{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:57:03Z","timestamp":1771019823336,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3148-z","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T07:32:47Z","timestamp":1527147167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016"],"prefix":"10.1186","volume":"18","author":[{"given":"Daniel J.","family":"Ruzicka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Tetsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"3148_CR1","doi-asserted-by":"publisher","unstructured":"Toshikuni N. Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver. 2016; \n                    https:\/\/doi.org\/10.5009\/gnl15458\n                    \n                  .","DOI":"10.5009\/gnl15458"},{"key":"3148_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/liv.12423","volume":"34","author":"R Schinazi","year":"2014","unstructured":"Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34:69\u201378.","journal-title":"Liver Int"},{"key":"3148_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/apt.12523","volume":"38","author":"B Maasoumy","year":"2013","unstructured":"Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013;38:1365\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"3148_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","volume":"5","author":"R Zampino","year":"2013","unstructured":"Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528\u201340.","journal-title":"World J Hepatol"},{"key":"3148_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13027-016-0076-7","volume":"11","author":"L Tang","year":"2016","unstructured":"Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agents Cancer. 2016;11:29.","journal-title":"Infect Agents Cancer"},{"key":"3148_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis"},{"key":"3148_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/ijms.3.47","volume":"3","author":"SL Chen","year":"2006","unstructured":"Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47\u201352.","journal-title":"Int J Med Sci"},{"key":"3148_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469\u201377.","journal-title":"J Infect Dis"},{"key":"3148_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","volume":"26","author":"JC Lauffenburger","year":"2014","unstructured":"Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;26:1073\u201382.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3148_CR10","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.3748\/wjg.v21.i24.7412","volume":"21","author":"U Vespasiani-Gentilucci","year":"2015","unstructured":"Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21:7412\u201326.","journal-title":"World J Gastroenterol"},{"key":"3148_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2334-12-86","volume":"12","author":"KS Louie","year":"2012","unstructured":"Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012;12:86.","journal-title":"BMC Infect Dis"},{"key":"3148_CR12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","volume":"13","author":"MJ Alter","year":"2007","unstructured":"Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436\u201341.","journal-title":"World J Gastroenterol"},{"key":"3148_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2957\/kanzo.55.589","volume":"55","author":"I Kamae","year":"2014","unstructured":"Kamae I, Kumada H, Kobayashi M, Ward T, Webster S, Yuan Y, et al. Epidemiology, treatment and health economics of hepatitis C in Japan (Review). Kanzo. 2014;55:589\u2013603. Japanese","journal-title":"Kanzo"},{"key":"3148_CR14","first-page":"129","volume":"65","author":"Y Karino","year":"2016","unstructured":"Karino Y. Innovation in hepatitis C treatment. J Japan Assoc Rural Med. 2016;65:129\u201335. Japanese","journal-title":"J Japan Assoc Rural Med"},{"key":"3148_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000252782","volume":"53","author":"H Chung","year":"2010","unstructured":"Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39\u201343.","journal-title":"Intervirology"},{"key":"3148_CR16","unstructured":"International Statistical Classification of Diseases and Related Health Problems 10th Revision. \n                    http:\/\/apps.who.int\/classifications\/icd10\/browse\/2016\/en\n                    \n                  . Accessed 24 May 2017."},{"key":"3148_CR17","unstructured":"EphMRA. EphMRA Anatomical Classification Guidelines.\u00a0\n                    https:\/\/www.ephmra.org\/media\/1090\/atcguidelines2016final.pdf\n                    \n                  .\u00a0Accessed 24 May 2017."},{"key":"3148_CR18","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","volume":"53","author":"G Guaraldi","year":"2011","unstructured":"Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120\u20136.","journal-title":"Clin Infect Dis"},{"key":"3148_CR19","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787\u201397.","journal-title":"Clin Infect Dis"},{"key":"3148_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561\u20137.","journal-title":"Clin Infect Dis"},{"key":"3148_CR21","doi-asserted-by":"publisher","first-page":"e0172159","DOI":"10.1371\/journal.pone.0172159","volume":"12","author":"LA Kondili","year":"2017","unstructured":"Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017;12:e0172159.","journal-title":"PLoS One"},{"key":"3148_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/hep.27920","volume":"63","author":"TB Dick","year":"2016","unstructured":"Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016;63:634\u201343.","journal-title":"Hepatology"},{"key":"3148_CR23","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","volume":"23","author":"JA Langness","year":"2017","unstructured":"Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: identification and management of drug-drug interactions. World J Gastroenterol. 2017;23:1618\u201326.","journal-title":"World J Gastroenterol"},{"key":"3148_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","volume":"58","author":"D Burger","year":"2013","unstructured":"Burger D, Back D, Buggisch P, Buti M, Crax\u00ed A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792\u2013800.","journal-title":"J Hepatol"},{"key":"3148_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40262-015-0317-8","volume":"55","author":"PS Badri","year":"2016","unstructured":"Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2016;55:275\u201395.","journal-title":"Clin Pharmacokinet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3148-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:08:38Z","timestamp":1558638518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3148-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3148"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3148-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was an observational study using de-identified medical claims data. Because the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects () do not apply to studies exclusively using de-identified data, we were not obligated to apply for an ethical approval for this study and to obtain informed consent in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DJR, JT, and GF are employed by MSD K.K. TK has no competing interests to declare on this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"237"}}